


## BMPS

<b>Cat. No.:</b>	HY-42146
<b>CAS No.:</b>	55750-62-4
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>10</sub> N <sub>2</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	266.21
<b>Target:</b>	ADC Linker
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	4°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : ≥ 45 mg/mL (169.04 mM) * "≥" means soluble, but saturation unknown.			
		<b>Solvent</b>	<b>Mass</b>	
		<b>Concentration</b>	<b>1 mg</b>	<b>5 mg</b>
	<b>Preparing Stock Solutions</b>		<b>10 mg</b>	
	<b>1 mM</b>	3.7564 mL	18.7822 mL	37.5643 mL
	<b>5 mM</b>	0.7513 mL	3.7564 mL	7.5129 mL
	<b>10 mM</b>	0.3756 mL	1.8782 mL	3.7564 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution			

## BIOLOGICAL ACTIVITY

<b>Description</b>	BMPS is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
<b>IC<sub>50</sub> &amp; Target</b>	Non-cleavable Linker
<b>In Vitro</b>	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA